Xenon Pharmaceuticals Inc. (XENE)
NASDAQ: XENE · Real-Time Price · USD
43.90
+0.46 (1.06%)
Dec 11, 2025, 12:23 PM EST - Market open
Xenon Pharmaceuticals Revenue
Xenon Pharmaceuticals had revenue of $7.50M in the twelve months ending September 30, 2025.
Revenue (ttm)
$7.50M
Revenue Growth
n/a
P/S Ratio
452.83
Revenue / Employee
$22,936
Employees
327
Market Cap
3.39B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | 9.43M | -9.00M | -48.83% |
| Dec 31, 2021 | 18.44M | -13.73M | -42.68% |
| Dec 31, 2020 | 32.17M | 25.34M | 371.02% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
XENE News
- 20 hours ago - Xenon Pharmaceuticals Inc. (XENE) Discusses Latest Phase III Updates for Azetukalner in Epilepsy and Commercial Launch Preparation Transcript - Seeking Alpha
- 6 days ago - Xenon Showcases New 48-Month Azetukalner OLE Study Data in Epilepsy at AES 2025 - GlobeNewsWire
- 6 days ago - Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 8 days ago - Xenon Announces Investor Webinar Highlighting Azetukalner and Epilepsy Data from AES 2025 - GlobeNewsWire
- 16 days ago - Xenon to Present New Azetukalner OLE Study Data in Epilepsy at AES 2025 - GlobeNewsWire
- 5 weeks ago - Xenon to Present at Upcoming Investor Conferences - GlobeNewsWire
- 5 weeks ago - Xenon Pharmaceuticals Inc. (XENE) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 5 weeks ago - Xenon Reports Third Quarter 2025 Financial Results & Business Update - GlobeNewsWire